Comparative Pharmacokinetics and Safety of 3 Different Formulations of TNX-102 2.8 mg SL Tablets and Cyclobenzaprine 5 mg Oral Tablet in Healthy Adults
- Conditions
- Healthy Adults
- Interventions
- Drug: TNX-102 SL Tablets at 2.8 mgDrug: TNX-102-B SL Tablets at 2.8 mgDrug: TNX-102-C SL Tablets at 2.8 mg
- Registration Number
- NCT01889173
- Lead Sponsor
- Tonix Pharmaceuticals, Inc.
- Brief Summary
Very low dose (VLD) cyclobenzaprine at bedtime has shown promise as a treatment for fibromyalgia, but the chemistry of cyclobenzaprine requires new formulation technology for bedtime use. The present trial is designed to assess the safety and tolerability of 3 different formulations of TNX-102 2.8 mg SL Tablets (a new formulation of cyclobenzaprine designed to result in increased dosage precision and decreased potential for morning grogginess) and to compare the bio-availability of 3 different formulations of TNX-102 2.8 mg SL Tablets (TNX-102 with potassium phosphate, TNX-102-B with sodium phosphate, and TNX-102-C with trisodium citrate) to that of cyclobenzaprine (5 mg tablets).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 24
- Healthy adults
- Male or female
- 18-65 years old
- Non-smoker
- BMI > 18.5 and < 30.0
- With medically acceptable form of contraception (female only)
- With signed informed consent
- Any clinically significant abnormality including ECG abnormalities or vital sign abnormalities (systolic blood pressure < 90 or > 140 mmHg,
- Diastolic blood pressure lower < 50 or > 90 mmHg, or heart rate < 50 or > 100 BPM)
- Any abnormal laboratory test (including positivity for Hep B, Hep C, HIV, and
- Hemoglobin < 128 g/L (males) or < 115 g/L (females) and hematocrit < 0.37 L/L (males) or < 0.32 L/L (females))
- History of alcohol or drug abuse or dependence within 1 year and/or positive drug, cotinine, or alcohol tests
- Use of any drug (within 30 days), supplement, or food (within 14 days) known to induce or inhibit hepatic drug metabolism prior to study medication
- Positive pregnancy test, breastfeeding or lactating
- Use of medication other than hormonal contraceptives or topical products, including OTC, natural health products, MAO inhibitors
- Participation in an investigational study within 30 days prior to dosing
- Donation of plasma (within 7 days), or donation or loss of blood of 50-499 mL (within 30 days), or of > 499 mL (within 56 days) prior to dosing.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description TNX-102 SL Tablets at 2.8 mg TNX-102 SL Tablets at 2.8 mg 1 x TNX-102 SL Tablets (with potassium phosphate) at 2.8 mg Cyclobenzaprine tablets Cyclobenzaprine tablets 1 x 5 mg cyclobenzaprine oral tablet TNX-102-B SL Tablets at 2.8 mg TNX-102-B SL Tablets at 2.8 mg 1 x TNX-102-B SL Tablets (with sodium phosphate) at 2.8 mg TNX-102-C SL Tablets at 2.8 mg TNX-102-C SL Tablets at 2.8 mg 1 x TNX-102-C SL Tablets (with trisodium citrate) at 2.8 mg
- Primary Outcome Measures
Name Time Method Measured levels of cyclobenzaprine and norcyclobenzaprine in plasma and urine 26 time points per period for blood assessment ; 2 pooled analyses in urine. Blood samples will be taken per period: within 30 minutes pre-dose and 2, 3.5, 5, 10, 20, 30, and 45 minutes and 1, 2, 2.5, 3, 3.33, 3.67, 4, 4.33, 4.67, 5, 5.5, 6, 8, 12, 16, 24, 36, and 48 hours post-dose. A single urine sample will be collected within 30 minutes pre-dose (one sample), and urine will be pooled from 0-24 and 24-48 hours post-dose.
Safety and tolerability of the 3 formulations of TNX-102 SL Tablets at 2.8 mg Continuously until the end (day 3) of the study period + Telephone follow-up 7-13 days after dosing (total duration: about 1 month) Every adverse events occurring during the study period will be reported.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
PharmaNet, Inc.
🇨🇦Quebec City, Quebec, Canada